Fibrotic process and drug metabolism in alcoholic liver disease

• Published in: Clinical pharmacology and therapeutics Vol. 40; no. 1; p. 46
• Main Authors: Sotaniemi, E A, Niemelä, O, Risteli, L, Stenbäck, F, Pelkonen, R O, Lahtela, J T, Risteli, J
• Format: Journal Article
• Language: English
• Published: United States 01-07-1986
• Subjects: Adult; Aged; Alcoholism - complications; Alcoholism - metabolism; Antigens - blood; Antipyrine - metabolism; Basement Membrane - metabolism; Collagen - biosynthesis; Collagen - metabolism; Cytochrome P-450 Enzyme System - metabolism; Female; Humans; Laminin - immunology; Liver Diseases, Alcoholic - complications; Liver Diseases, Alcoholic - metabolism; Liver Diseases, Alcoholic - pathology; Liver Function Tests; Male; Middle Aged
• ISSN: 0009-9236
• DOI: 10.1038/clpt.1986.138

The effect of fibrosis on drug metabolism in alcoholic liver disease was evaluated in a comparison of the concentrations of serum aminoterminal propeptide of type III procollagen and basement membrane (BM; 7S domain of type IV collagen and laminin) antigens with in vitro (cytochrome P-450) and in vivo (antipyrine) drug metabolism in 67 alcoholics classified by liver histology. Alcoholics with intact or fatty liver had rapid or normal drug metabolism and normal collagen metabolism. Alcoholics with a fatty liver plus fibrosis or active cirrhosis had reduced drug metabolism and elevated levels of serum markers for collagen and BM metabolism. Alcoholics with inactive cirrhosis who had received therapy with enzyme inducers had a tendency toward normal drug and collagen metabolism parameters. Antipyrine metabolism, but not P-450 content, was related to the levels of serum type III collagen and BM markers. The fibrotic process, especially BM formation, creates a mechanical barrier that may prevent contact between blood and hepatocytes, thus delaying substrate availability.